HomeInsightsStock Comparison

Dr Reddys Laboratories Ltd vs Neuland Laboratories Ltd Stock Comparison

Dr Reddys Laboratories Ltd vs Neuland Laboratories Ltd Stock Comparison

Last Updated on: May 14, 2025

Key Highlights

  • The Latest Trading Price of Dr Reddys Laboratories Ltd is ₹ 1215 as of 14 May 10:38.
  • The P/E Ratio of Dr Reddys Laboratories Ltd changed from 25.6 on March 2020 to 18.4 on March 2024 . This represents a CAGR of -6.39% over 5 yearsThe P/E Ratio of Neuland Laboratories Ltd changed from 22.5 on March 2020 to 27 on March 2024 . This represents a CAGR of 3.71% over 5 years.
  • The Market Cap of Dr Reddys Laboratories Ltd changed from ₹ 51797 crore on March 2020 to ₹ 102679 crore on March 2024 . This represents a CAGR of 14.67% over 5 yearsThe Market Cap of Neuland Laboratories Ltd changed from ₹ 363.66 crore on March 2020 to ₹ 8058 crore on March 2024 . This represents a CAGR of 85.83% over 5 years.
  • The revenue of Dr Reddys Laboratories Ltd for the Mar '25 is ₹ 9056 crore as compare to the Dec '24 revenue of ₹ 8535 crore. This represent the growth of 6.1% The revenue of Neuland Laboratories Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 457.72 crore. This represent the decline of -100%.
  • The ebitda of Dr Reddys Laboratories Ltd for the Mar '25 is ₹ 2525 crore as compare to the Dec '24 ebitda of ₹ 2427 crore. This represent the growth of 4.04% The ebitda of Neuland Laboratories Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 146.28 crore. This represent the decline of -100%.
  • The net profit of Dr Reddys Laboratories Ltd changed from ₹ 1405 crore to ₹ 1586 crore over 8 quarters. This represents a CAGR of 6.27% The net profit of Neuland Laboratories Ltd changed from ₹ 61.88 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% .
  • The Dividend Payout of Dr Reddys Laboratories Ltd changed from 14.14 % on March 2020 to 15.37 % on March 2024 . This represents a CAGR of 1.68% over 5 yearsThe Dividend Payout of Neuland Laboratories Ltd changed from 16.25 % on March 2020 to 6.03 % on March 2024 . This represents a CAGR of -17.99% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Dr Reddys Laboratories Ltd

  • Dr Reddy's Laboratories Limited (DRL) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
  • Through its three businesses - Pharmaceutical Services &Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including Active Pharmaceutical Ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations.
  • The company's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.
  • Dr. Reddy's operates in markets across the globe.
  • Its major markets include - USA, India, Russia & CIS countries, and Europe. Dr Reddy's Laboratories Limited was incorporated in 1984 in Hyderabad.

About Neuland Laboratories Ltd

  • Incorporated on January 7, 1984, Neuland Laboratories Limited (NLL) is promoted by Davuluri Sucheth Rao.
  • The Company is engaged in manufacturing and selling of bulk drugs such as salbutamol sulphate, terbutaline sulphate, labetalol hydrochloride and ciprofloxacin.
  • Neuland Drugs & Pharmaceuticals Pvt.
  • Ltd., a company set up by the same promoters to manufacture bulk drugs was merged with the Company effective from April, 1992.
  • NLL manufactures bulk drugs. The Company came out with its initial public offering in Apr.'94 at a premium of Rs 35 aggregating Rs 5.69 cr, to part-finance the capacity expansion to manufacture bulk drugs and to diversify its product-mix.

Dr Reddys Laboratories Ltd News Hub

News

Dr Reddys Lab jumps after Q4 PAT rises 22% YoY

Revenue from operations rose 20% year-on-year to Rs 8,506 crore, compared to Rs 7,083 cror...

Read more

12 May 2025 14:50

News

Dr Reddys Laboratories AGM scheduled

Dr Reddys Laboratories announced that the 41th Annual General Meeting(AGM) of the company ...

Read more

10 May 2025 10:17

News

Dr Reddys Lab Q4 PAT rises 22% YoY

Revenue from operations rose 20% year-on-year to Rs 8,506 crore, compared to Rs 7,083 cror...

Read more

10 May 2025 10:52

News

Board of Dr Reddys Laboratories recommends Final Dividend

Dr Reddys Laboratories announced that the Board of Directors of the Company at its meeting...

Read more

09 May 2025 17:01

News

Dr Reddys announces cessation of subsidiary in Louisiana

Dr. Reddy's Laboratories Inc., USA, a wholly owned subsidiary of the Company, has successf...

Read more

24 Mar 2025 13:48

News

Dr Reddys Laboratories to conduct board meeting

Dr Reddys Laboratories will hold a meeting of the Board of Directors of the Company on 9 M...

Read more

22 Mar 2025 11:01

Neuland Laboratories Ltd News Hub

News

Neuland Laboratories to announce Quarterly Result

Neuland Laboratories will hold a meeting of the Board of Directors of the Company on 15 Ma...

Read more

25 Apr 2025 10:43

News

Neuland Laboratories Ltd Spurts 2.02%

Neuland Laboratories Ltd gained 2.02% today to trade at Rs 13000. The BSE Healthcare index...

Read more

17 Apr 2025 09:30

News

Neuland Laboratories appoints Head - Manufacturing

Neuland Laboratories announced that Parag Deshmukh has been appointed as Head - Manufactur...

Read more

10 Mar 2025 15:29

News

Neuland Laboratories receives affirmation in credit ratings

Neuland Laboratories announced that India Ratings and Research has affirmed the credit rat...

Read more

10 Mar 2025 15:26

News

Neuland Laboratories Ltd leads gainers in 'A' group

Vesuvius India Ltd, Pfizer Ltd, Data Patterns (India) Ltd and Orchid Pharma Ltd are among ...

Read more

24 Feb 2025 12:00

News

Neuland Laboratories Ltd Falls 3.78%

Neuland Laboratories Ltd lost 3.78% today to trade at Rs 13142.7. The BSE Healthcare index...

Read more

12 Feb 2025 09:30

SWOT Analysis Of Neuland Laboratories Ltd

Strength

5

S

Weakness

2

W

Opportunity

0

O

Threats

0

T

SWOT Analysis Of Dr Reddys Laboratories Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Neuland Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Dr Reddys Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Dr Reddys Laboratories Ltd and Neuland Laboratories Ltd

Which company has a larger market capitalization, Dr Reddys Laboratories Ltd or Neuland Laboratories Ltd?

Market cap of Dr Reddys Laboratories Ltd is 100,702 Cr while Market cap of Neuland Laboratories Ltd is 16,152 Cr

What are the key factors driving the stock performance of Dr Reddys Laboratories Ltd and Neuland Laboratories Ltd?

The stock performance of Dr Reddys Laboratories Ltd and Neuland Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Dr Reddys Laboratories Ltd and Neuland Laboratories Ltd?

As of May 14, 2025, the Dr Reddys Laboratories Ltd stock price is INR ₹1206.8. On the other hand, Neuland Laboratories Ltd stock price is INR ₹12589.45.

How do dividend payouts of Dr Reddys Laboratories Ltd and Neuland Laboratories Ltd compare?

To compare the dividend payouts of Dr Reddys Laboratories Ltd and Neuland Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions